Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisXSWX:VTRS +0.33%60 Debt-to-EBITDA is 6.65 as of Mar. 2026, which is 35% above its 10-year median of 4.94. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.96. The stock has 8 warning signs investors should review. Among 690 Drug Manufacturers companies, Viatris ranks worse than 84.64% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Viatris's Debt-to-EBITDA or its related term are showing as below:
XSWX:VTRS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -37.17 Med: 4.94 Max: 13.13
Current: 5.91
During the past 13 years, the highest Debt-to-EBITDA Ratio of Viatris was 13.13. The lowest was -37.17. And the median was 4.94.
XSWX:VTRS's Debt-to-EBITDA is ranked worse than 84.64% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs XSWX:VTRS: 5.91
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Viatris Debt-to-EBITDA Related Terms
Viatris Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Viatris's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VTRS vs UTHR, NBIX, ELAN: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viatris's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Viatris (XSWX:VTRS) has a Debt-to-EBITDA of 6.65 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viatris. This is 35% above median its historical median of 4.94. According to the industry distribution chart, Viatris ranks #584 out of 690 companies in the Drug Manufacturers industry, placing it in the top 84.6%.
Is Viatris' Debt-to-EBITDA too high?
Viatris' current Debt-to-EBITDA of 6.65 is 35% above median its 10-year median of 4.94. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Viatris' value of 6.65 is 303% above this industry median. Based on the distribution chart, Viatris ranks #584 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Debt-to-EBITDA compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #584 out of 690 companies for Debt-to-EBITDA. This places Viatris in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. Viatris' value of 6.65 is 303% above this benchmark. While the company's 10-year median is 4.94 vs. the industry median of 1.65, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Debt-to-EBITDA of 6.65 is 303% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viatris. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Debt-to-EBITDA is 6.65, which is 35% above median its own 10-year median of 4.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Debt-to-EBITDA of 6.65. The stock's GF Value™ is CHF8.96, compared to a current price of CHF14.01 — trading 56.4% above its estimated fair value. The current Debt-to-EBITDA is 6.65, which is 35% above median its 10-year median of 4.94 and 303% above the Drug Manufacturers industry median of 1.65. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Debt-to-EBITDA is 6.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF14.01 is trading 56.4% above its estimated GF Value™ of CHF8.96.
Key valuation signals for XSWX:VTRS:
Debt-to-EBITDA: 6.65 (35% above median its 10-year median of 4.94)
GF Value™: CHF8.96 vs. price of CHF14.01 (56.4% above fair value)
Industry Position: 303% above the Drug Manufacturers median (#584 of 690)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for XSWX:VTRS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
